Drugs, sex, money and power: an HPV vaccine case study
- PMID: 19505744
- DOI: 10.1016/j.healthpol.2009.05.002
Drugs, sex, money and power: an HPV vaccine case study
Abstract
In this paper we compare the experiences of seven industrialized countries in considering approval and introduction of the world's first cervical cancer-preventing vaccine. Based on case studies, articles from public agencies, professional journals and newspapers we analyse the public debate about the vaccine, examine positions of stakeholder groups and their influence on the course and outcome of this policy process. The analysis shows that the countries considered here approved the vaccine and established related immunization programs exceptionally quickly even though there still exist many uncertainties as to the vaccine's long-term effectiveness, cost-effectiveness and safety. Some countries even bypassed established decision-making processes. The voice of special interest groups has been prominent in all countries, drawing on societal values and fears of the public. Even though positions differed among countries, all seven decided to publicly fund the vaccine, illustrating a widespread convergence of interests. It is important that decision-makers adhere to transparent and robust guidelines in making funding decisions in the future to avoid capture by vested interests and potentially negative effects on access and equity.
Similar articles
-
Benefits, cost requirements and cost-effectiveness of the HPV16,18 vaccine for cervical cancer prevention in developing countries: policy implications.Reprod Health Matters. 2008 Nov;16(32):86-96. doi: 10.1016/S0968-8080(08)32409-4. Reprod Health Matters. 2008. PMID: 19027626
-
Lessons from the failure of human papillomavirus vaccine state requirements.Clin Pharmacol Ther. 2007 Dec;82(6):760-3. doi: 10.1038/sj.clpt.6100397. Epub 2007 Oct 31. Clin Pharmacol Ther. 2007. PMID: 17971822
-
The Australian funding debate on quadrivalent HPV vaccine: a case study for the national pharmaceutical policy.Health Policy. 2008 Dec;88(2-3):250-7. doi: 10.1016/j.healthpol.2008.03.012. Epub 2008 May 12. Health Policy. 2008. PMID: 18468714
-
Country recommendations on the inclusion of HPV vaccines in national immunization programmes among high-income countries, June 2006-January 2008.Vaccine. 2008 Dec 2;26(51):6529-41. doi: 10.1016/j.vaccine.2008.08.067. Vaccine. 2008. PMID: 18805453 Review.
-
Human papillomavirus quadrivalent vaccine: a look behind the numbers.Ann Pharmacother. 2009 Apr;43(4):740-4. doi: 10.1345/aph.1L483. Epub 2009 Mar 10. Ann Pharmacother. 2009. PMID: 19276314 Review.
Cited by
-
Cost-effectiveness analysis of introducing universal childhood rotavirus vaccination in Bangladesh.Hum Vaccin Immunother. 2018 Jan 2;14(1):189-198. doi: 10.1080/21645515.2017.1356962. Epub 2017 Dec 12. Hum Vaccin Immunother. 2018. PMID: 29099653 Free PMC article.
-
The risk of HIV transmission at each step of the HIV care continuum among people who inject drugs: a modeling study.BMC Public Health. 2017 Jul 25;17(1):614. doi: 10.1186/s12889-017-4528-9. BMC Public Health. 2017. PMID: 28738861 Free PMC article.
-
Provincial elections and timing of cancer drug funding.Curr Oncol. 2016 Jun;23(3):154-63. doi: 10.3747/co.23.3024. Epub 2016 Jun 9. Curr Oncol. 2016. PMID: 27330343 Free PMC article.
-
Effect of human papillomavirus (HPV) vaccination on clinical indicators of sexual behaviour among adolescent girls: the Ontario Grade 8 HPV Vaccine Cohort Study.CMAJ. 2015 Feb 3;187(2):E74-E81. doi: 10.1503/cmaj.140900. Epub 2014 Dec 8. CMAJ. 2015. PMID: 25487660 Free PMC article.
-
Political and institutional influences on the use of evidence in public health policy. A systematic review.PLoS One. 2013 Oct 30;8(10):e77404. doi: 10.1371/journal.pone.0077404. eCollection 2013. PLoS One. 2013. PMID: 24204823 Free PMC article. Review.
